Q-omics provides the consensus-scored CDH18 profile across patient tissues and cancer cell-line models. CDH18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDH18 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CDH18 RNA expression shows 12,756 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where CDH18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH18 survival associations across molecular data types. CDH18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH18 RNA expression–survival associations across cancer types. High CDH18 expression shows unfavorable associations in KIRC, UVM, LIHC, SCLC and LUAD, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDH18 RNA expression.
This table summarizes CDH18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CDH18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH18 shows lower tumor expression in KIRC, KIRP, COAD and KICH and higher tumor expression in UCEC and BRCA. The KIRC box plot shows higher CDH18 RNA expression in normal versus tumor tissue (log2 FC = −0.425, t-test p < 0.001).
This table shows molecular features associated with CDH18 in patient tissues and cancer cell lines. In patient samples, CDH18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
